Survival and outcomes for co-infection of chronic hepatitis C with and without cirrhosis and COVID-19: A multicenter retrospective study

Table 5 Comparison between patients with and without liver cirrhosis

			No liver cirrhosis 61 (48.8%)	Liver cirrhosis 64 (51.2%)	P value
Hemoglobin (mg/dL)			12 ± 2	12 ± 2	0.85
Platelet count (× 1000/cmm)			193 ± 107	171 ± 107	0.36
TLC (× 1000/cmm)			12 ± 10	9 ± 5	0.31
Serum creatinine (mg/dL)			1.58 ± 1.89	1.21 ± 0.76	0.59
Total bilirubin (mg/dL)			3 ± 4	3 ± 5	0.79
Serum albumin (g/dL)			3.3 ± 0.7	3.1 ± 0.6	0.36
Alanine transaminase (U/L)			67 ± 67	50 ± 40	0.21
Aspartate transaminase (U/L)			60 ± 37	101 ± 137	0.89
CT pattern	Consolidations and ground-glass opacities		4 (6.55%)	28 (43.75%)	< 0.001
	Ground-glass opacities		57 (93.45%)	36 (56.25%)
Lesion distribution on CT	Bilateral		58 (95.1%)	64 (100.0%)	0.11
	Unilateral		3 (4.9%)	0
COVID-19 severity	Moderate		50 (81.96%)	35 (54.69%)	0.003
	Severe		11 (18.04%)	29 (45.31%)
Azithromycin			33 (54.1%)	39 (60.9%)	0.47
Paracetamol			16 (26.2%)	29 (45.3%)	0.04
Supplementary vitamin C			37 (60.7%)	48 (75.0%)	0.12
Supplementary zinc			33 (54.1%)	36 (56.3%)	0.85
Lactoferrin			3 (4.9%)	15 (23.4%)	0.004
Other antibiotics			28 (45.9%)	43 (67.2%)	0.019
Anticoagulants		LMWH	28 (45.9%)	28 (43.8%)	1
		Warfarin	1 (1.6%)	2 (3.1%)	1
Steroids			16 (26.2%)	22 (34.4%)	0.339
Alive (discharged)			52 (85.25%)	31 (48.44%)	< 0.001
Died at the hospital			9 (14.75%)	33 (51.56%)

TLC: Thin layer chromatography; CT: Computed tomography; COVID-19: Coronavirus disease 2019.